<DOC>
	<DOCNO>NCT00197236</DOCNO>
	<brief_summary>This study evaluate immune response safety GSK Biologicals 2-dose inactivate hepatitis A vaccine administer diphtheria , tetanus pertussis combination ( DTaP ) vaccine Haemophilus influenza type B ( Hib ) vaccine child 15 month age . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immunogenicity Safety Havrix™ Co-Administered With Diphtheria , Tetanus Pertussis Haemophilus b Vaccine Children Aged 15 Months</brief_title>
	<detailed_description>An open , control comparison Havrix™ administer alone Infanrix™ ActHIB . The three group evaluate : 1 ) Havrix™ alone , 2 ) Havrix™ + Infanrix™ ActHIB 3 ) Infanrix™ ActHIB follow Havrix™ one month later .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects whose parents/guardians believe investigator willing comply requirement protocol A male female child 12 13 month age time entry Enrolment Phase , Subjects must previously receive three dos DTaP Hib vaccine first year life . The three dos DTaP vaccine must administer either Infanrix™ Pediarix™ three dos Hib vaccine must administer ActHIB™ , HibTITER™ , OmniHIB™ . Subjects , 15 month age , least six month elapse since third dose Infanrix™ Pediarix™ , Written inform consent obtain parent guardian subject , Free obvious health problem establish medical history historydirected physical examination enter study , Parents/guardian subject must telephone able contact telephone . Use investigational nonregistered drug vaccine study vaccine ( ) within 31 day precede first dose study vaccine , plan use study period , Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination plan administration time study period . Planned administration administration vaccine foreseen study protocol period 42 day 31 day dose study vaccine ( ) . Previous vaccination DTaP use commerciallyavailable brand Infanrix™ Pediarix™ Hib use commerciallyavailable brand ActHIB™ , HibTITER™ OmniHIB™ . Previous vaccination three dos DTaPcontaining vaccine three dos Hibcontaining vaccine . Previous vaccination hepatitis A , History know exposure hepatitis A , History diphtheria , tetanus , pertussis and/or Haemophilus influenza type b , Known exposure diphtheria , tetanus , pertussis and/or Haemophilus influenza type b within 31 day prior start study , History nonresponse vaccine current routine immunization schedule , Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , A family history congenital , hereditary infectious immunodeficiency parental risk factor HIV infection , History allergic disease/reactions hypersensitivity likely exacerbate component Havrix™ , Infanrix™ ActHIB™ include 2phenoxyethanol , neomycin gelatin , History hypersensitivity/allergic reaction latex Major congenital defect serious chronic illness , History neurologic disorder Acute disease time vaccination . Administration immunoglobulins and/or blood product within three month prior first dose study vaccine plan administration time entire study period , i.e. , Enrolment Phase , Active Phase Extended Safety Followup Phase</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>13 Months</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Hepatitis A</keyword>
</DOC>